Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 operating results announced for quarter ended June 30, 2026.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 operating results announced for quarter ended June 30, 2026
- Press release containing financial details filed as Exhibit 99.01
- Results announcement gives investors access to the company’s latest quarterly performance update
Item EX-99.1 · Exhibit EX-99.1
- Q2 product revenue $13.5M vs $2.0M, driven by TONMYA net sales of $11.0M
- TONMYA prescriptions reached 12,592, up 100% quarter-over-quarter, while refills rose 207%
- Coverage expanded to 136M lives, with 145M expected after approximately 9M Medicare lives begin coverage January 1, 2027
- Operating loss widened to $42.5M as R&D reached $19.4M and SG&A $36.0M for launch and pipeline investment
- Cash fell to $176.2M from $207.6M at year-end; management expects resources to fund operations into early Q2 2027, implying financing sensitivity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.